论文部分内容阅读
目的观察奥扎格雷钠联用纤溶酶治疗急性进展型脑梗死的疗效。方法对64例急性进展型脑梗死患者,随机分为治疗组和对照组。对照组用奥扎格雷钠,治疗组奥扎格雷钠联用纤溶酶,两组对照比较。结果治疗组可使进展期明显缩短,神经功能缺损程度改善快且好,治愈率和有效率均高于对照组(P<0.05);实验室指标显示,治疗组比对照组纤维蛋白原明显降低,治疗前后与对照组相比较均有明显差异(P<0.001)。而凝血酶原时间和出、凝血时间无明显变化。结论奥扎格雷钠联用纤溶酶治疗急性进展型脑梗死效果好,具有良好的安全性。
Objective To observe the efficacy of ozagrel combined with plasmin in the treatment of acute progressive cerebral infarction. Methods 64 patients with acute progressive cerebral infarction were randomly divided into treatment group and control group. The control group with sodium ozagrel, the treatment group ozagrel sodium combined plasmin, the two groups compared. Results The treatment group significantly shortened the progression, the neurological deficits improved rapidly and well, and the cure rate and the effective rate were higher than those of the control group (P <0.05). The laboratory indexes showed that the fibrinogen of the treatment group was significantly lower than that of the control group , Before and after treatment compared with the control group were significantly different (P <0.001). The prothrombin time and out, coagulation time no significant change. Conclusion Ozagrel combined with plasmin in the treatment of acute progressive cerebral infarction is effective and has good safety.